Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23356315 | 0.88 | TRPA1 (0.42) | KDM4ETRPA1 | |
| SCHEMBL29804247 | 0.79 | CYP1A2 (0.41) | SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30678436 | 0.79 | CYP1A2 (0.41) | SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL24683460 | 0.79 | CYP1A2 (0.41) | SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29804420 | 0.79 | ALDH1A1 (0.44) | SMN1; SMN2PLA2G2A | |
| SCHEMBL24683928 | 0.79 | ALDH1A1 (0.44) | SMN1; SMN2PLA2G2A | |
| SCHEMBL23356292 | 0.78 | HSD17B10 (0.43) | SMN1; SMN2 | |
| SCHEMBL29804203 | 0.77 | SCN10A (0.42) | — | |
| SCHEMBL24683495 | 0.77 | SCN10A (0.42) | — | |
| SCHEMBL30678441 | 0.77 | SCN10A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-112689633-B | For inhibiting Nav1.8 Pyridinecarboxamide Compounds | 利伯研究所公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | disclosed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN2A | SMN1; SMN2 189/4885PLA2G2A 2466/4885KDM4E 1196/4885 |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | SCN8A, SCN1A, SCN2A | SMN1; SMN2 189/4885PLA2G2A 2466/4885KDM4E 1196/4885 |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN1B | SMN1; SMN2 456/4885PLA2G2A 3935/4885KDM4E 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.